CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 36 enrolled
Drug / intervention
ranibizumabdrug
Likely dose
ranibizumab 0.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02342392
NCT02342392Phase 3Completed
CompareCT.gov

Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

Universiti Sains Malaysia·interventional·Posted Jan 19, 2015·Updated Jan 19, 2015

In Brief

A Phase 3 clinical trial evaluating ranibizumab for Pterygium. Completed, enrolled 36 participants.

Detailed Summary

The purpose of this study is to evaluate the pterygium vascularity and size before and after intralesional ranibizumab injection and to evaluate its recurrence rate following pterygium excision surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPterygium
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 19, 2015
Enrollment StartSep 1, 2012
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 11.5 years ago

Interventions

ranibizumabdrug

Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.